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Abstract
Background: The frequency and clinically important characteristics of incidental (18)F-fluorodeoxyglucose ([18 F]FDG)
positron emission tomography (PET) uptake in the gastrointestinal tract (GIT) on PET/CT imaging in adults remain elusive.
Methods: All PET/CT reports from 1/1/2000 to 12/31/2009 at a single tertiary referral center were reviewed; clinical
information was obtained from cases with incidental (18)F-FDG uptake in the GIT, with follow-up through October, 2012.
Results: Of the 41,538 PET/CT scans performed during the study period, 303 (0.7 %) had incidental GIT uptake. The
most common indication for the PET/CT order was cancer staging (226 cases, 75 %), with 74 % for solid and 26 % for
hematologic malignancies. Of those with solid malignancy, only 51 (17 %) had known metastatic disease. The most
common site of GIT uptake was the colon, and of the 240 cases with colonic uptake, the most common areas of
uptake were cecum (n = 65), sigmoid (n = 60), and ascending colon (n = 50). Investigations were pursued for the GIT
uptake in 147 cases (49 %), whereas 51 % did not undergo additional studies, largely due to advanced disease. There
were 73 premalignant colonic lesions diagnosed in 56 cases (tubular adenoma, n = 36; tubulovillous adenoma with low
grade dysplasia, n = 27; sessile serrated adenoma, n = 4; tubulovillous adenoma with high grade dysplasia, n = 3; villous
adenoma, n = 3), and 20 cases with newly diagnosed primary colon cancer. All 20 (100 %) patients with malignant
colonic lesions had a focal pattern of [18 F]FDG uptake. Among cases with a known pattern of [18 F]FDG uptake, 98 %
of those with premalignant lesions had focal [18 F]FDG uptake. Eighteen (90 %) of the cases with newly diagnosed
colon cancer were not known to have metastatic disease of their primary tumor. Areas of incidental uptake in the
ascending colon had the greatest chance (42 %) of being malignant and premalignant lesions than in any other area.
Conclusion: Focality of uptake is highly sensitive for malignant and premalignant lesions of the GIT. In patients
without metastatic disease, incidental focal [18]FDG uptake in the GIT on PET/CT imaging warrants further evaluation.
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Background
Positron emission tomography (PET) is a nuclear imaging
technique that has been widely used in oncology for the
detection of neoplasia [1]. In 1998, the Centers for Medi-
care and Medicaid Services (CMS) approved coverage for
PET imaging in the evaluation of indeterminate solitary
pulmonary nodules and initial staging of lung cancer. Since
that time, CMS has expanded its coverage for various
investigations of different types of cancers including
breast, lung, colorectal, esophageal, head and neck,
lymphoma and melanoma [2]. The use of PET imaging
continues to increase, and is now standard in oncologic
practice.
Fluorine-18 fluorodeoxyglucose ([18 F]FDG) is the
most commonly used radiolabeled tracer in PET scans.
[18 F]FDG is taken up intracellularly by various tissues
and accumulate during glucose metabolism, which oc-
curs at a relatively higher rate in cancer cells. However,
cancer cells are not the only cells that are metabolically
hyperactive. Inflammation, infection and other non-
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neoplastic conditions such as hyperplastic colorectal
polyps can lead to increased 18 F- FDG accumulation
[3]. For this reason, PET scans have a high sensitivity but
a low specificity for colorectal cancer [3, 4].
PET/computed tomography (CT) scanning offers two
technologies that combine metabolic abnormality detec-
tion with anatomic localization [5, 6]. Compared to PET
alone, this combination has been shown to be superior
in localizing lesions and differentiating between physio-
logic and malignant uptake of [18 F]FDG [6].
Given the use of PET/CT has become increasingly com-
mon in oncologic practice, it is not surprising that with in-
creased use comes incidental [18 F]FDG uptake that was
not anticipated, forcing the ordering physician to decide
how to address such findings. Numerous studies explored
incidental [18 F]FDG uptake in the GIT and reported rates
ranging from 0.5 % to 2.6 % [7–14]. Studies have shown
that a focal pattern of incidental [18 F]FDG uptake in the
GIT is more likely to be malignant than a non-focal pattern
[7, 15]. However, these studies are limited by relatively
small numbers.
The purpose of our study was to determine the fre-
quency, clinical characteristics and patterns of [18 F]FDG
uptake in lesions found incidentally in the GIT on PET/
CT imaging in adults.
Methods
We searched the Mayo Clinic electronic record database
from 1/1/2000 to 12/31/2009 for patients greater than
18 years of age who had the terms “bowel”, “colonoscopy”
and “intestine” in their whole body PET/CT reports. All of
these radiology reports were reviewed by a single investi-
gator who identified cases with incidental uptake on PET/
CT imaging. An incidental finding was defined as an area
of [18 F]FDG uptake in the GIT that could not be ex-
pected based on the patient’s known medical history at
the time of the PET/CT scan. Patients whose indication
for PET/CT imaging was gastrointestinal cancer were ex-
cluded. The medical records were reviewed by a single in-
vestigator for demographic information; medical history;
indication for PET/CT imaging; location and pattern of
[18 F]FDG tracer uptake; date of most recent previous
PET/CT study, if applicable; work-up launched to investi-
gate the incidental finding, if any; new diagnoses from
subsequent investigational studies. Follow-up was per-
formed through October 2012. The study was approved
by the Mayo Clinic Institutional Review Board.
Results
Among the 41,538 PET/CT scans performed during the
study period, 303 (0.7 %) scans from 288 unique patients
had incidental GIT uptake. The incidence of incidental
[18 F]FDG uptake in the GIT on PET/CT scans increased
substantially during the study period (Fig. 1). The mean
age for all patients, patients with malignant lesions and
patients with premalignant lesions was 66.9 years (stand-
ard deviation 11.8), 71.1 years (standard deviation 11.6)
and 68.5 years (standard deviation 12.0), respectively.
Two hundred and forty-one scans reported a pattern of
uptake, with 232 with a focal pattern, eight with a diffuse
pattern and one with both diffuse and focal components.
A diffuse pattern of uptake was noted in multiple colonic
locations (one case), sigmoid and rectum (one case), rec-
tum only (one case), small bowel (one case), entire colon
(one case), ascending colon (one case), not specified (two
cases). the 303 cases, 147 (49 %) underwent further inves-
tigations. The remaining 51 % did not undergo further in-
vestigations largely due to advanced cancer. Studies
pursued were colonoscopy (108 cases), extended or rou-
tine esophagogastroduodenoscopy (EGD) (seven cases),
CT abdomen (four cases), CT enterography (three cases),
balloon-assisted endoscopy (one case), capsule study (one
case), flexible sigmoidoscopy (one case), CT colonography
(one case), follow-up PET scan (three cases), laparoscopy
(one case), and multiple investigations (seventeen cases).
In nineteen other cases, endoscopy (colonoscopy in eight-
een cases and sigmoidoscopy in one case) was recom-
mended, but results were unavailable because these
studies were either not performed or the patient was lost
to follow-up. Among all 303 cases, the most common in-
dication for the PET/CT order was cancer staging (226
cases, 75 %), with 74 % (167 cases) for solid and 26 % (59
cases) for hematologic malignancies; other indications in-
cluded follow-up of an indeterminate nodule/mass (9 %,
28 cases) and paraneoplastic features (6 %, seventeen
cases). Of those with solid malignancy, only 51 (17 %) had
known metastatic disease.
Among all patients, patients with malignant lesions
and patients with premalignant lesions, females com-
prised 44 % (126 females), 45 % (nine females) and 45 %
(24 females), respectively. There were 20 malignant le-
sions identified in 20 patients, representing 14 % of all
patients who underwent additional investigations. The
malignant lesions were found in the cecum (25 % cases),
Fig. 1 Number of PET/CT studies with incidental FDG uptake by
year, 2000–2009
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ascending colon (25 % cases), transverse colon (20 %
cases), descending colon (15 % cases) and rectum (15 %
cases) (Table 1). Lesions in the ascending colon had the
greatest likelihood of being malignant or pre-malignant;
42 % (21 cases) of all lesions in the ascending colon were
identified as premalignant or malignant. Eighteen (90 %)
of the cases with newly diagnosed colon cancer were not
known to have metastatic disease of their primary
tumor. For five cases, the T stage was not known be-
cause surgical resections were not performed at our in-
stitution. Of the remaining fifteen cases, ten were T3,
three were T4 and one was T1. Six cases had nodal in-
volvement and three had distant metastases. Figure 2
demonstrates a case in which a rectal adenocarcinoma
was eventually diagnosed in a patient undergoing PET/
CT scan for evaluation of a pulmonary nodule.
There were 73 premalignant lesions identified in 56
PET/CT scans among 53 patients, representing 38 % areas
of incidental [18 F]FDG uptake that underwent additional
investigations. There were 36 tubular adenomas, 27 tubu-
lovillous adenomas with low grade dysplasia, four sessile
serrated adenomas, three tubulovillous adenomas with
high grade dysplasia and three villous adenomas.
Among all PET/CT scans in our study, 55 (18 %) had
areas of incidental uptake that were endoscopically ex-
amined and found to be non-neoplastic. Thirty-eight
(69 %) of these scans were noted to have a focal pattern
of [18 F]FDG uptake. Among these 55 scans, 39 (71 %)
had no abnormalities identified.
Specifically outside the colorectum, [18 F]FDG uptake
was noted in the esophagus (five cases), stomach (five
cases), duodenum (four cases), jejunum (one case), ileum
(nine cases) and other locations in the abdomen that were
not specifically ascribed to a particular organ (sixteen
cases). Endoscopic work up revealed the following path-
ology in these cases: erosive esophagitis (two cases), tubulo-
villous adenoma in the duodenum (one case), hyperplastic
polyp in the gastric cardia (one case), antral erosion (one
case), celiac disease (one case), Barrett’s esophagus (one
case), and NSAID-induced ileitis (one case).
Of the eight areas with a diffuse pattern of uptake in
the bowel, five were endoscopically examined and one
preneoplastic lesion (tubular adenoma) was identified in
the sigmoid. In two additional cases, further work up re-
vealed small bowel intussusception (one case) and celiac
disease (one case). Of the five remaining cases with an
unknown etiology for the [18 F]FDG uptake, one patient
was noted to be on metformin (dose was 500 mg twice
daily). There were three polyps of unknown histology
because one was not biopsied and two were obtained at
an outside hospital.
Table 2 demonstrates patterns of [18 F]FDG uptake in
areas that turned out to be malignant, premalignant and
non-neoplastic. The sigmoid colon was the most common
site of incidental [18 F]FDG uptake that corresponded to
no known pathology. Among cases of known pattern of
[18 F]FDG uptake, a focal pattern was seen in 100 %, 98 %
and 88 % of colonic lesions that turned out to be malig-
nant, pre-malignant and non-neoplastic, respectively.
Discussion
Due to the wide use of PET/CT imaging in oncology, inci-
dental [18 F]FDG uptake in the GIT is found frequently. In
our study, incidental [18 F]FDG uptake in the GIT was
found in 0.7 % patients who had PET/CT imaging. Treglia
and colleagues reported a 1.1 % prevalence of a focal pat-
tern of colorectal uptake of [18 F]FDG [8]. Peng and col-
leagues reported a similar prevalence of 1.35 % [9]. In the
present study, 0.6 % incidental [18 F]FDG uptake had a
focal pattern of [18 F]FDG uptake. Possible reasons for this
disparity in reported prevalence may be differences in pa-
tient populations and practice settings. Compared to other
studies, the present study is the largest, spanning 10 years
and more than 41,000 whole-body [18 F]FDG PET scans.
Our findings underscore previously reported data that
diffuse [18 F]FDG uptake is not suggestive of a neoplastic
lesion. None of the malignant lesions in our study had a
diffuse pattern of uptake. Only one patient had a diffuse
pattern of [18 F]FDG uptake on a PET scan and an even-
tual diagnosis of a premalignant lesion; however, the area
of the premalignant lesion was different from the area of
the [18 F]FDG uptake. This patient had celiac disease and
a diffuse pattern of [18 F]FDG uptake in the small bowel,
cecum, left colon and sigmoid colon. A colonoscopy was
performed two months later to further investigate findings
of the abnormal PET scan and revealed a tubular adenoma
Table 1 Five most common colon locations of 18F-fluorodeoxyglucose ([18 F]FDG) uptake in patients who underwent colonoscopya
Malignant lesions, no. (%) Premalignant lesions, no. (%) All, no. (%)
Cecum 5 (25) Cecum 16 (28) Cecum 65 (21)
Ascending colon 5 (25) Ascending colon 16 (28) Sigmoid 60 (20)
Transverse colon 4 (20) Sigmoid 13 (23) Ascending colon 50 (17)
Descending colon 3 (15) Transverse colon 6 (11) Transverse colon 36 (12)
Rectum 3 (15) Descending colon 4 (7) Descending colon 29 (10)
a = 20 areas of uptake in patients that were later found to have malignancies, 56 areas of uptake in patients that were later found to have premalignant lesions,
303 all areas of incidental uptake
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in the ascending colon. In 2002, Tatlidil and colleagues ex-
amined 27 patients with incidental PET uptake in the
gastrointestinal tract (GIT) who subsequently underwent
endoscopy [7]. The authors concluded that nodular high
[18 F]FDG uptake should be investigated with colonos-
copy, a diffuse pattern of uptake is likely to be normal and
segmental high uptake is suggestive of inflammation [7].
The present study offers a significantly larger patient
population to support the same conclusion regarding a
diffuse pattern of [18 F]FDG uptake.
Among the 147 cases of incidental [18 F]FDG uptake
who underwent further investigations, more than half
(52 %) had colorectal pathology in the form of malignant
or premalignant lesions. This is similar to the frequency
reported by the study reported by Treglia and colleagues
that found 64 % of patients who had further investiga-
tions were diagnosed with malignant or premalignant le-
sions [8]. Given the high likelihood that an area of
incidental [18 F]FDG uptake in the GIT may represent a
malignant or premalignant lesion, our data supports pre-
viously stated recommendations to perform a colonos-
copy for further investigation.
Among cases in which the pattern of [18 F]FDG uptake
was known, 40 % had focal 18 F- FDG uptake in areas that
were later found to be endoscopically normal. Possible eti-
ologies are active smooth muscle, metabolically active mu-
cosa, swallowed secretions, or colonic microbial uptake.
The cecum and ascending colon were the most com-
mon areas of pathology; each location had 21 areas of
incidental [18 F]FDG uptake that turned out to be ma-
lignant or premalignant. Areas of incidental uptake in
the ascending colon had the greatest chance (42 %) of
being malignant and premalignant lesions than in any
other area. These findings are different from those re-
ported by others, in which the greatest proportion of
malignant and premalignant lesions was found in the
distal colon and rectum [8, 9].
The sigmoid colon was the most common site of inciden-
tal [18 F]FDG uptake that corresponded to no known path-
ology, per endoscopy. Treglia and colleagues reported
similar findings with the largest number of non-neoplastic
lesions in the sigmoid colon [8]. However, other reports de-
scribe an increased false-positive rate of [18 F]FDG uptake
in the ascending colon [9, 16, 17]. A possible explanation
for increased uptake in the ascending colon could be diar-
rhea, since this has been shown to cause focal [18 F]FDG
uptake on PET scans [18]. Other investigators proposed
that a higher uptake within the ascending colon and cecum
Fig. 2 Focal [18 F]FDG uptake in a 79 year old male who was evaluated for an isolated right upper lobe pulmonary nodule. (a) coronal and (b)
sagittal PET slices show indeterminate FDG avid foci (arrows) within the rectum. Area of increased uptake (arrow) was localized by PET/CT (c).
Tissue biopsy revealed invasive moderately differentiated (grade 3 of 4) adenocarcinoma







Focal uptake, no. (% of cases
with known pattern of uptake)
12 (100) 46 (98) 38b (88)
Diffuse uptake, no (% of cases
with known pattern of uptake)
0 (0) 1 (2) 4 (9)
a = 54 areas of uptake
b = 12 patients had an unknown pattern of uptake
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may be secondary to a higher concentration of lymphocytes
in the region [16]. The high false positive rate observed in
the sigmoid colon in the present study remains without ex-
planation, although given diverticular disease is most com-
mon in the sigmoid colon, one has to wonder if a mildly
inflamed diverticulum could account for this.
Our study has several limitations. The study is retro-
spective and is therefore vulnerable to sampling bias.
Additionally, half of cases with incidental [18 F]FDG up-
take were not further investigated and the pathology of
those lesions remains unknown in this retrospective co-
hort. Therefore, the evidence in this study may not be
sufficient to provide an accurate prevalence of premalig-
nant and malignant lesions in patients with incidental
[18 F]FDG uptake on PET/CT imaging. Our data is lim-
ited to a single, tertiary referral center and our patient
population may not be representative of the general pa-
tient population at non-tertiary referral centers; however,
given it is the largest sample for which incidental GIT
uptake is reported, it is likely more representative com-
pared to smaller multicenter studies.
Conclusion
Focal [18]FDG uptake in the GIT on PET/CT imaging is
highly sensitive for malignant and premalignant lesions
of the GIT. In patients without metastatic disease,
incidental focal [18]FDG uptake in the GIT on PET/CT
imaging warrants further evaluation.
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